Alzheimer's disease and age-related memory decline (preclinical)
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
An unfortunate result of the rapid rise in geriatric populations worldwide is the increasing prevalence of age-related cognitive disorders such as Alzheimer’s disease (AD). AD is a devastating neurodegenerative illness that is characterized by a profound impairment of cognitive function, marked physical disability, and an enormous economic burden on the afflicted individual, caregivers, and society in general. The rise in elderly populations is also resulting in an increase in individuals with related (potentially treatable) conditions such as “Mild Cognitive Impairment” (MCI) which is characterized by a less severe (but abnormal) level of cognitive impairment and a high-risk for developing dementia. Even in the absence of a diagnosable disorder of cognition (e.g., AD, MCI), the perception of increased forgetfulness and declining mental function is a clear source of apprehension in the elderly. This is a valid concern given that even a modest impairment of cognitive function is likely to be associated with significant disability in a rapidly evolving, technology-based society. Unfortunately, the currently available therapies designed to improve cognition (i.e., for AD and other forms of dementia) are limited by modest efficacy, adverse side effects, and their effects on cognitive function are not sustained over time. Accordingly, it is incumbent on the scientific community to develop safer and more effective therapies that improve and/or sustain cognitive function in the elderly allowing them to remain mentally active and productive for as long as possible. As diagnostic criteria for memory disorders evolve, the demand for pro-cognitive therapeutic agents is likely to surpass AD and dementia to include MCI and potentially even less severe forms of memory decline. The purpose of this review is to provide an overview of the contemporary therapeutic targets and preclinical pharmacologic approaches (with representative drug examples) designed to enhance memory function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Mammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724
The role of acetylcholine in learning and memory
Hasselmo, M. E. (2006) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2006.09.002 · Cited by 1,693
HDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261 · cited 1×
“On an individual level, AD significantly shortens life expectancy and it is one of the major causes of physical disability, institutionalization, and decreased quality of life among the elderly (reviewed Qiu et al., 2009).”
BackgroundEffects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons
Frey, U., Huang, Y.-Y., & Kandel, E. R. (1993) · Science · doi:10.1126/science.8389057 · Cited by 1,218 · cited 2×
“Activation of the cAMP/PKA/CREB and cGMP/PKG/CREB pathway has been implicated in synaptic plasticity such as long-term potentiation (LTP) and cognitive function (Frey et al., 1993; Son et al., 1998; Blokland et al., 2006).”
BackgroundTerry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159
Self-citationPhysiological Diversity of Nicotinic Acetylcholine Receptors Expressed by Vertebrate Neurons
McGehee, D. S., & Role, L. W. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.002513 · Cited by 1,022 · cited 1×
“Nicotinic receptors are composed of five membrane-spanning subunits that form a pentameric arrangement around a water-filled pore (Jones et al., 1999; Karlin 2002; McGehee and Role, 1995).”
BackgroundMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Bartus, R. T. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7397 · Cited by 829
Molecular biology of 5-HT receptors
Hannon, J., & Hoyer, D. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.03.020 · Cited by 815
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713 · cited 2×
“For example atomoxetine was observed to improve reversal learning in rats and monkeys (Seu et al., 2009) while modafinil has been overved to improve gognition in several domains including working memory and episodic memory in both rodent models and humans (reviewed, Minzenberg and Carter, 2008).”
BackgroundFreedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678 · cited 1×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript hippocampus, certain cortical layers, and the hypothalamus, making these receptors intriguing targets for cognition enhancement (Freedman et al., 1995).”
BackgroundMuscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Wess, J., Eglen, R. M., & Gautam, D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2379 · Cited by 637
Impey, S., Mark, M., Villacres, E. C., Poser, S., Chavkin, C., & Storm, D. R. (1996) · Neuron · doi:10.1016/s0896-6273(00)80120-8 · Cited by 593 · cited 1×
“…PDE1, PDE2, PDE3, PDE10 and PDE11 are capable of hydrolyzing both cAMP and cGMP. PDE inhibitors (PDE-I) increase intracellular levels of cAMP and/or cGMP which can lead to gene transcription by activating the CREP signaling pathways (Impey et al., 1996; Lu and Hawkins, 2002; Tully et al., 2003).”
BackgroundBallard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Vitolo, O. V., Sant'Angelo, A., Costanzo, V., Battaglia, F., Arancio, O., & Shelanski, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172504199 · Cited by 534
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442 · cited 3×
“…Huang et al., 2007 MEM1018 Zhang et al., 2005 MEM 1091 Zhang et al., 2005 Rolipram Barad et al., 1998; Comery et al., 2005; Egawa et al., 1997; Gong et al., 2004; Rutten et al., 2007, 2008; Zhang and O'Donnell, 2000; Zhang et al., 2000 PDE5 Inhibitors Sildenafil Devan et al., 2004, 2006;…”
BackgroundM1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice
Caccamo, A., Oddo, S., Billings, L. M., Green, K. N., Martinez-Coria, H., Fisher, A., & LaFerla, F. M. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.020 · Cited by 417
Nicotinic receptor subtypes and cognitive function
Levin, E. D. (2002) · Journal of Neurobiology · doi:10.1002/neu.10151 · Cited by 354
Clinical Pharmacology of Nicotine
Benowitz, N. L. (1986) · Annual Review of Medicine · doi:10.1146/annurev.me.37.020186.000321 · Cited by 352
The Physiological Role of 5-HT2AReceptors in Working Memory
Williams, G. V., Rao, S. G., & Goldman-Rakic, P. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02843.2002 · Cited by 311 · cited 2×
“…and Ogren, 2003; Pitsikas et al., 2003 WAY 101405 antagonist Hirst et al., 2008 5-HT2A MDL 100,907 antagonist Meneses, 1999; Roth et al., 2004; Williams et al., 2002; Winstanley et al., 2003 EMD 281014 antagonist Terry et al., 2005b Ketanserin antagonist Levin and Rezvani, 2007 Mianserin…”
BackgroundSubtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders
Conn, P. J., Jones, C. K., & Lindsley, C. W. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.002 · Cited by 286
Winstanley, C. A., Chudasama, Y., Dalley, J. W., Theobald, D. E. H., Glennon, J. C., & Robbins, T. W. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1398-x · Cited by 234 · cited 3×
“…5HT2A receptor antagonist MDL 100,907 improved visuospatial attention and decreased impulsivity in the rat 5-choice serial reaction time task (Winstanley et al., 2003) and oral administration of the 5HT2A receptor antagonist EMD 281014 improved medium and long retention interval performance…”
BackgroundDysregulation of Protein Kinase A Signaling in the Aged Prefrontal Cortex
Ramos, B. P., Birnbaum, S. G., Lindenmayer, I., Newton, S. S., Duman, R. S., & Arnsten, A. F. T. (2003) · Neuron · doi:10.1016/s0896-6273(03)00694-9 · Cited by 218 · cited 2×
“Behaviorally, rolipram has shown improvements in object recognition, spatial reference, working and associative memory behavioral tasks in young and aged rodents (Bach et al., 1999; Barad et al., 1998; Monti et al., 2006; Ramos et al., 2003; Rutten et al., 2006.”
BackgroundWilens, T. E., & Decker, M. W. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.002 · Cited by 164
Grossberg, G., & Thomas, S. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6666 · Cited by 151 · cited 2×
“Approval of memantine was based on three randomized, double-blind, placebo-controlled clinical trials in moderate to severe AD (reviewed, Thomas and Grossberg, 2009).”
BackgroundMethodHowe, W. M., Ji, J., Parikh, V., Williams, S., Mocaër, E., Trocmé-Thibierge, C., & Sarter, M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.9 · Cited by 150 · cited 2×
“…α2β4 agonist Schneider et al., 2003 ABT-418 α4β2 agonist Prendergast et al., 1998 ABT-594 α4β2 agonist Buccafusco et al., 2007 S-38232 α4β2 agonist Howe et al., 2010 ABT-089 α4β2 partial agonist Decker et al., 1997 Ispronicline/AZD-3480 α4β2 partial agonist Gatto et al.,…”
BackgroundDrug development for Alzheimer's disease: where are we now and where are we headed?
Sabbagh, M. N. (2009) · The American journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.003 · Cited by 147 · cited 1×
“…the 5-HT1A receptor antagonist lecozotan (SRA-333) was shown to be safe and well tolerated in healthy young and elderly subjects (Patat et al., 2009) and a clinical phase II trial in mild to moderate AD patients was recently completed, though the outcome hasn’t been reported (Sabbagh, 2009).”
BackgroundDesensitization of nicotinic acetylcholine receptors as a strategy for drug development
Buccafusco, J. J., Beach, J. W., & Terry, A. V. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.145292 · Cited by 144
Self-citationLevin, E. D., & Rezvani, A. H. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.019 · Cited by 129 · cited 2×
“…ketanserin failed to show improvements in the radial arm maze or operant signal detection task in rats and coadministration of ketanserin with either acute or chronic administration of nicotine attenuated the enhanced attentional performance produced by nicotine (Levin and Rezvani, 2007).”
BackgroundRodefer, J. S., Nguyen, T. N., Karlsson, J.-J., & Arnt, J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301654 · Cited by 126 · cited 2×
“…et al., 2007 SB 271046 antagonist Callahan et al., 2004; Foley et al., 2004; King et al., 2004; Loiseau et al., 2008; Marcos et al., 2008; Rodefer et al., 2008; Routledge et al., 2000 SB 357134 antagonist Rogers and Hagan, 2001; Stean et al., 2002 SB 399885 antagonist Hatcher et al.,…”
BackgroundGatto, G. J., Bohme, G. A., Caldwell, W. S., Letchworth, S. R., Traina, V. M., Obinu, M. C., Laville, M., Reibaud, M., Pradier, L., Dunbar, G., et al. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00010.x · Cited by 111 · cited 2×
“…agonist Buccafusco et al., 2007 S-38232 α4β2 agonist Howe et al., 2010 ABT-089 α4β2 partial agonist Decker et al., 1997 Ispronicline/AZD-3480 α4β2 partial agonist Gatto et al., 2004 Varenicline/Chantix® α4β2/α7 partial agonist/full agonist Rollema et al., 2009 GTS-21 α7 partial agonist Buccafusco…”
BackgroundDecker, M. W., Bannon, A. W., Curzon, P., Gunther, K. L., Brioni, J. D., Holladay, M. W., Lin, N.-H., Li, Y., Daanen, J. F., Buccafusco, J. J., et al. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37015-6 · Cited by 88
Cited by
Kouémou, N. E., Taiwe, G. S., Moto, F. C. O., Pale, S., Ngoupaye, G. T., Njapdounke, J. S. K., Nkantchoua, G. C. N., Pahaye, D. B., & Bum, E. N. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00847 · Cited by 55
Yadav, M. K., Singh, S. K., Singh, M., Mishra, S. S., Singh, A. K., Tripathi, J. S., & Tripathi, Y. B. (2019) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2019.247 · Cited by 26
“Alzheimer’s disease is a progressive neurodegenerative disease which is characterised by the loss of learning and memory abilities with ageing [1].”
BackgroundHosseini, Z., Mansouritorghabeh, F., Kakhki, F. S. H., Hosseini, M., Rakhshandeh, H., Hosseini, A., Hasanpour, M., Iranshahi, M., & Rajabian, A. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-021-00898-y · Cited by 24
Metadata
- Authors
- Terry, A. V., Callahan, P. M., Hall, B., & Webster, S. J.
- Venue
- Pharmacology Biochemistry and Behavior
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 99
- Issue
- 2
- Pages
- 190-210
- ISSN
- 0091-3057 (ISSN-L)
- OpenAlex
- W2026305700
- Cited by
- 86
- References
- 38
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.